In an ominous move, the FDA — under pressure from antiabortion groups and GOP members of Congress — has launched a new safety study of mifepristone that is a thinly veiled move to restrict mail and telehealth access to the abortion pill.
“The administration is aiming for a robust study that will withstand legal criticism,” administration officials told the WSJ, previewing the intended outcome.
Read more at Talking Points Memo and the WSJ